FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer (READ MORE HERE).
Statins are cholesterol-lowering medications used widely to..
Stanley Liauw, MD:
University of Chicago – Chicago, IL
Ralph Weichselbaum, MD, Chairman, Radiation and Cellular Oncology Department, Director, Chicago Tumor Institute, and Director, Ludwig Center for Metastasis Research, University of Chicago.
Walter Stadler, MD, Director, Genitourinary Program, Chair, Cancer Research Center's Clinical Trials Review Committee, and Associate Dean for Clinical Research, University of Chicago.
Immunotherapy activates the body’s own immune system..
Joshua Lang, MD, MS:
University of Wisconsin Carbone Comprehensive Cancer Center – Madison, WI
Douglas McNeel, MD, PhD, Associate Professor of Medicine, Section of Hematology/Oncology at the University of Wisconsin Carbone Comprehensive Cancer Center.
PTEN (phosphatase and tensin homologue on chromosome..
Tamara Lotan, MD:
Johns Hopkins University
Angelo DeMarzo, MD, PhD and Elizabeth Platz, ScD
Circulating Tumor Cells (CTCs) detach from metastatic..
Richard Lee, MD, PhD:
Massachusetts General Hospital Cancer Center
Matthew R. Smith, MD, PhD
T-cells are a type of fighter blood..
Jihyun Lee, PhD:
University of Pennsylvania
Carl June, MD
Developing a Novel Quantitative Total Bone Imaging..
Assistant Professor of Medicine
University of Wisconsin School of Medicine and Public Health UW Carbone Cancer Center
Smart Nanoparticles for Imaging and Treatment of..
Bren Professor of Chemistry
California Institute of Technology
GPR30 as a potential therapeutic target for..
Hung-Ming Lam, PhD:
University of Washington
Shuk-Mei Ho, PhD
Prostate tumor cells upregulate and secrete an..
Aaron LeBeau, PhD:
University of Minnesota
Henry VanBrocklin, PhD and Phillip Febbo, MD
Targeting active urokinase plasminogen activator for therapy using an internalizing human antibody
While most men with prostate cancer initially..
Zhenfei Li, PhD:
Cleveland Clinic Foundation
Nima Sharifi, MD; Eric Klein, MD
A Novel Abiraterone Metabolite as a Predictive Biomarker for Clinical Response to Abiraterone
A highly aggressive subtype of treatment-resistant prostate..
John Kyung Lee, MD:
University of California, Los Angeles
Owen Witte, MD
Therapeutic Targeting of N-Myc-Driven Human Small Cell Neuroendocrine Prostate Cancer
Despite initial response, most prostate cancers will..
Christopher J. Logothetis, MD –:
The University of Texas MD Anderson Cancer Center Mechanisms of Resistance to Androgen Biosynthesis Inhibition in Castration-Resistant Prostate Cancer Bone Metastases
Gary Gallick, PhD; Sankar Maity, PhD; Randall Millikan, MD, PhD; Mark Bedford, PhD; Eleni Efstathiou, MD, PhD
As prostate cancer advances and spreads, it..
Dr. Glenn Liu, MD –:
UW Carbone Cancer Center Imaging Biomarkers of Treatment Response Using NaF PET/CT Imaging: a Prostate Cancer Clinical Trials Consortium (PCCTC) Effort
Michael Morris; William Dahut, MD; Steven Larson, MD; Peter Choyke, MD; Robert Jeraj, PhD